Affymax, Inc. is a biopharmaceutical company previously committed to developing novel drugs to improve the treatment of serious and often life-threatening conditions. Our vision was to become a leader in the nephrology and specialty care space by delivering innovative therapeutic offerings to patients and healthcare providers before a nationwide voluntary recall of OMONTYS® (peginesatide) Injection in February 2013. In March 2013 Affymax commenced a review of strategic alternatives.
|Type||Public / Private|
Top 5 Recent Tweets
|March 15, 2023||DavidCranmerUn1||Alex Zaffaroni in 1993, and was eventually based in Santa Clara, California, United States. It began as a unit in A… https://t.co/G3ardX0AbL|
|March 15, 2023||DavidCranmerUn1||model in rabbits using retro-viral transduction techniques. Dr. Daniel St. Louis is currently SVP and GM of Expre… https://t.co/Cs8Bs70MkL|